 |
September 18, 2008
New Maturation Inhibitor Enters Phase 2 Testing
Vivecon (MPC-9055), a new maturation inhibitor, is moving into early Phase 2 studies. The experimental antiretroviral will be studied in HIV-positive people to determine the proper dose of the drug, according to a press release from Myriad Genetics.
Maturation inhibitors prevent HIV from properly assembling into infectious particles, which occurs at the end of the virus’s life cycle.
Vivecon was tested in HIV-negative volunteers to assess its short-term safety and determine how well the body absorbs it. According to Myriad, Vivecon achieved therapeutic drug levels in the blood and did not cause significant side effects.
Search: maturation inhibitor, Vivecon, MPC-9055, Myriad Genetics
Scroll down to comment on this story.
Previous Comments:
[Go to top]
|
|
